3.63
6.20%
-0.24
After Hours:
3.70
0.07
+1.93%
SAB Biotherapeutics Inc stock is currently priced at $3.63, with a 24-hour trading volume of 12,221.
It has seen a -6.20% decreased in the last 24 hours and a -21.09% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.89 pivot point. If it approaches the $3.69 support level, significant changes may occur.
Previous Close:
$3.87
Open:
$3.75
24h Volume:
12,221
Market Cap:
$33.49M
Revenue:
-
Net Income/Loss:
$-42.19M
P/E Ratio:
-5.7619
EPS:
-0.63
Net Cash Flow:
$-25.32M
1W Performance:
-9.48%
1M Performance:
-21.09%
6M Performance:
+327.56%
1Y Performance:
+326.61%
SAB Biotherapeutics Inc Stock (SABS) Company Profile
Name
SAB Biotherapeutics Inc
Sector
Industry
Phone
605 679 6980
Address
2100 East 54th Street North, Sioux Falls
SAB Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
SAB Biotherapeutics Inc Stock (SABS) Latest News
SAB Biotherapeutics Enhances Board with Medical Expert - TipRanks.com - TipRanks
TipRanks
SAB Biotherapeutics (NASDAQ:SABS) Stock Price Up 3.8% - Defense World
Defense World
Broker Revenue Forecasts For SAB Biotherapeutics, Inc. (NASDAQ:SABS) Are Surging Higher - Yahoo Lifestyle UK
Yahoo Lifestyle UK
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors - GlobeNewswire
GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
GlobeNewswire Inc.
SAB Biotherapeutics Provides SAB-142 Trial Update
GlobeNewswire Inc.
SAB Biotherapeutics Inc Stock (SABS) Financials Data
SAB Biotherapeutics Inc (SABS) Net Income 2024
SABS net income (TTM) was -$42.19 million for the quarter ending December 31, 2023, a -125.14% decrease year-over-year.
SAB Biotherapeutics Inc (SABS) Cash Flow 2024
SABS recorded a free cash flow (TTM) of -$25.32 million for the quarter ending December 31, 2023, a +1.21% increase year-over-year.
SAB Biotherapeutics Inc (SABS) Earnings per Share 2024
SABS earnings per share (TTM) was -$7.74 for the quarter ending December 31, 2023, a -79.58% decline year-over-year.
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Cap:
|
Volume (24h):